AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NRIX

Hansen Gwenn sold $36K of NRIX

Hansen Gwenn (Chief Scientific Officer) sold 1,452 shares of Nurix Therapeutics, Inc. (NRIX) at $25.00 on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hansen Gwenn
Published Oct 15, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NRIX
Neutral
high confidence
Mentioned
$NRIX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRIXNeutralLow
01

Why it matters

The sale is small and pre‑arranged, so market impact is expected to be negligible.

02

Market read

A routine insider sale with limited materiality; unlikely to affect trading decisions.

03

What to watch

The 10b5‑1 plan may be routine and pre‑scheduled, reducing any informational edge.

Relevance 2/10Novelty 2/10Timing: same day filing

Background

Form 4 filings disclose insider transactions; they are primary sources for regulatory disclosures.

Company-level read

Ticker impact

$NRIXNeutralHigh confidence
Context

Chief Scientific Officer Hansen Gwenn sold 1,452 shares of Nurix Therapeutics for $36,300 on 2026-10-15 via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A 10b5‑1 sale by a senior officer signals personal liquidity need but the amount ($36K) is trivial relative to market cap.

Market effects

Sector

Minimal; biotech sector not materially affected by a small insider sale.

Regional

None; the filing is U.S. SEC‑based and does not affect regional markets.

Global

None; the transaction is company‑specific and low‑scale.

Counterpoint

What could challenge this read

If the insider had insider knowledge, the sale could hint at upcoming negative news, warranting a short‑term watch.

Key entities

  • company
    Nurix Therapeutics, Inc.

    Biotech firm developing targeted protein degradation therapies.

  • person
    Hansen Gwenn

    Chief Scientific Officer of Nurix Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NRIX insider trading history →

Related articles

Med

Nurix Therapeutics stock is up, what you need to know

Nurix Therapeutics (NRIX) shares rose 3.4% after appointing Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development, including the BTK degrader bexobrutideg partnered with Roche. The stock closed at $16.33, up 2.8% from the previous close. Nurix has faced volatility, including a 39.8% drop last week due to Sanofi ending a Phase 1 study. The company has $1.1B in cash, funding operations into 2029.

tradingview.com
$NRIXHighAI 8/10

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

Nurix Therapeutics (NRIX) shares fell 38% after Sanofi (SNY) terminated development of a key Phase I immunology candidate, SAR448272 (NX-3911), under their collaboration. Despite this, the rest of the collaboration remains intact, and Nurix maintains a strong cash position. Analysts note Nurix's potential in the oral protein degrader space, particularly its partnership with Roche (RO) for bexobrutideg (NX-5948), which targets a $48B market opportunity across five diseases.

genengnews.com
$NRIXMedAI 8/10

Nurix to present bexobrutideg data at ASH meeting

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.

investing.com